Literature DB >> 21240546

Antihypertensive drugs and inflammation in acute ischemic stroke as a predictor factor of future cardiovascular mortality.

Gulcin Benbir1, Birsen Ince, Emre Kumral, Zeki Ongen, Hakan Kultursay, Lale Tokgozoglu, Ali Oto, Hasan Tuzun.   

Abstract

The beneficial effects of antihypertensive drugs in secondary stroke prevention could not be based on their effects on lowering hypertension only.In this prospective study, the status of blood pressure, treatment regimens, new atherothrombotic event, blood sampling for hs-CRP and fibrinogen were asked at initial visit, 6th, and 12th months in 226 patients with atherothrombotic stroke.Eighty-seven percent of patients had an antihypertensive regimen, but hypertension control was achieved in 34.1% of patients.Neither use of six different antihypertensive drug regimens nor the change in blood pressure levels showed any difference on new atherothrombotic events, outcomes or survival rates.On the other hand, the higher levels of hs-CRP at baseline were found to be associated with higher mortality rates (p=0.020).Our findings emphasize the predictive role of inflammation in future cardiovascular mortality in patients with acute ischemic stroke, indicating that inflammatory mediators underlying the atherothrombotic process play a more important role than it is assumed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21240546     DOI: 10.1007/s10753-010-9290-4

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  33 in total

1.  C-reactive protein and outcome after ischemic stroke.

Authors:  K W Muir; C J Weir; W Alwan; I B Squire; K R Lees
Journal:  Stroke       Date:  1999-05       Impact factor: 7.914

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  Is C-reactive protein an independent risk factor for essential hypertension?

Authors:  L E Bautista; P López-Jaramillo; L M Vera; J P Casas; A P Otero; A I Guaracao
Journal:  J Hypertens       Date:  2001-05       Impact factor: 4.844

5.  High sensitivity C-reactive protein as an independent risk factor for essential hypertension.

Authors:  Ki Chul Sung; Jung Yul Suh; Bum Soo Kim; Jin Ho Kang; Hyang Kim; Man Ho Lee; Jung Ro Park; Sun Woo Kim
Journal:  Am J Hypertens       Date:  2003-06       Impact factor: 2.689

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Association between blood pressure and C-reactive protein levels in acute ischemic stroke.

Authors:  Mario Di Napoli; Francesca Papa
Journal:  Hypertension       Date:  2003-11-03       Impact factor: 10.190

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

9.  Blood pressure control in Italy: results of recent surveys on hypertension.

Authors:  Massimo Volpe; Giuliano Tocci; Bruno Trimarco; Enrico Agabiti Rosei; Claudio Borghi; Ettore Ambrosioni; Alessandro Menotti; Alberto Zanchetti; Giuseppe Mancia
Journal:  J Hypertens       Date:  2007-07       Impact factor: 4.844

10.  The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.

Authors:  Nadia A Khan; Finlay A McAlister; Norman R C Campbell; Ross D Feldman; Simon Rabkin; Jeff Mahon; Richard Lewanczuk; Kelly B Zarnke; Brenda Hemmelgarn; Marcel Lebel; Mitchell Levine; Carol Herbert
Journal:  Can J Cardiol       Date:  2004-01       Impact factor: 5.223

View more
  2 in total

1.  Systems analysis of eleven rodent disease models reveals an inflammatome signature and key drivers.

Authors:  I-Ming Wang; Bin Zhang; Xia Yang; Jun Zhu; Serguei Stepaniants; Chunsheng Zhang; Qingying Meng; Mette Peters; Yudong He; Chester Ni; Deborah Slipetz; Michael A Crackower; Hani Houshyar; Christopher M Tan; Ernest Asante-Appiah; Gary O'Neill; Mingjuan Jane Luo; Rolf Thieringer; Jeffrey Yuan; Chi-Sung Chiu; Pek Yee Lum; John Lamb; Yves Boie; Hilary A Wilkinson; Eric E Schadt; Hongyue Dai; Christopher Roberts
Journal:  Mol Syst Biol       Date:  2012-07-17       Impact factor: 11.429

2.  Serum apelin is associated with left ventricular hypertrophy in untreated hypertension patients.

Authors:  Lijun Ye; Fenghua Ding; Liang Zhang; Anna Shen; Huaguo Yao; Liehua Deng; Yuanlin Ding
Journal:  J Transl Med       Date:  2015-09-05       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.